Expression of IL-17 on Breast Cancer Mice Treated by Combination of Phyllanthus Urinaria and Catharanthus roseus Extract

Authors

  • Aya Shofiyah Biology Master Program, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia
  • M. Sasmito Djati Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya. Jl. Veteran, Malang 65145, East Java, Indonesia
  • Muhaimin Rifa'i Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya. Jl. Veteran, Malang 65145, East Java, Indonesia

DOI:

https://doi.org/10.21776/ub.jels.2022.012.02.05

Abstract

This study aimed to evaluate the effect of combination Phyllanthus urinaria and Catharanthus roseus in breast cancer mice based on the expression of IL-17. 7,12-Dimethylbenz(α)anthracene (DMBA) was injected intraperitoneally into normal mice at dose 1.5 mg.kg-1 weight to obtain breast cancer mice. Total of 24 experimental mice divided into normal mice (N), breast cancer mice (K), breast cancer mice with cisplatin (C) treatment (5 mg.kg-1 weight), breast cancer mice with combination extract Dose 1 (P. urinaria 500 mg.kg-1 weigt + C. roseus 15mg.kg-1 weight), breast cancer mice with combination extract Dose 2 (P. urinaria 1000 mg.kg-1 weight + C. roseus 75mg.kg-1 weight), and breast cancer with combination extract Dose 3 (P. urinaria 2000 mg.kg-1 weight + C. roseus 375 mg.kg-1 weight). Cheral was given orally for 14 days. The level of IL-17 was evaluated by flow cytometry analysis. The combination can suppress the expression of IL-17 which down regulation of IL-17 indicate a good prognosis for the breast cancer mice, for 6.17% in breast cancer condition to 0.93% with Dose 3 treatment. The combination can be used as immunomodulatory agent in humoral immunity through the regulation of IL-17.

Keywords: Breast cancer, Catharanthus roseus, IL-17, Phyllanthus urinaria

Downloads

Published

2022-06-30

Issue

Vol. 12 No. 2 (2022)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).